Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit.

Publisher: Elsevier Country of Publication: England NLM ID: 101463825 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0210 (Electronic) Linking ISSN: 18780210 NLM ISO Abbreviation: Prim Care Diabetes Subsets: MEDLINE

Original Publication: Kidlington, Oxford : Elsevier

Sodium-Glucose Transporter 2 Inhibitors*; Benzhydryl Compounds/*adverse effects ; Diabetes Mellitus, Type 2/*drug therapy ; Genital Diseases, Female/*chemically induced ; Genital Diseases, Male/*chemically induced ; Glucosides/*adverse effects ; Hypoglycemic Agents/*adverse effects ; Mycoses/*chemically induced; Aged ; Chi-Square Distribution ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/metabolism ; Female ; Genital Diseases, Female/diagnosis ; Genital Diseases, Female/epidemiology ; Genital Diseases, Female/microbiology ; Genital Diseases, Male/diagnosis ; Genital Diseases, Male/epidemiology ; Genital Diseases, Male/microbiology ; Humans ; Logistic Models ; Male ; Medical Audit ; Middle Aged ; Mycoses/diagnosis ; Mycoses/epidemiology ; Mycoses/microbiology ; Odds Ratio ; Recurrence ; Risk Factors ; Sodium-Glucose Transporter 2/metabolism ; Time Factors ; Treatment Outcome ; United Kingdom/epidemiology

Introduction: Treatment of type 2 diabetes with sodium-glucose cotransporter 2 (SGLT2) inhibitors may result in genital fungal infections. We investigated possible risk factors for developing such infections among patients treated with the SGLT2 inhibitor dapagliflozin.
Methods: The Association of British Clinical Diabetologists (ABCD) collected data on patients treated with dapagliflozin in routine clinical practice from 59 diabetes centres. We assessed possible associations of patient's age, diabetes duration, body mass index, glycated haemoglobin, renal function, patient sex, ethnicity and prior genital fungal infection, urinary tract infection, urinary incontinence or nocturia, with the occurrence of ≥1 genital fungal infection within 26 weeks of treatment.
Results: 1049 out of 1116 patients (476 women, 573 men) were analysed. Baseline characteristics were, mean±SD, age 56.7±10.2years, BMI 35.5±6.9kg/m ² and HbA 1c 9.4±1.5%. Only patient sex (13.2% women vs 3.3% men) and prior history of genital fungal infection (21.6% vs 7.3%) were found to be associated with occurrence of genital fungal infections after dapagliflozin treatment, adjusted OR 4.22 [95%CI 2.48,7.19], P<0.001 and adjusted OR 2.41 [95% CI 1.04,5.57], P=0.039, respectively.
Conclusion: Women and patients with previous genital fungal infections had higher risks of developing genital fungal infections with dapagliflozin treatment.
(Copyright © 2017 Primary Care Diabetes Europe. All rights reserved.)

Keywords: Dapagliflozin; Genital fungal infection; Genital mycotic infection; SGLT2 inhibitor; Thrush

0 (Benzhydryl Compounds)
0 (Glucosides)
0 (Hypoglycemic Agents)
0 (SLC5A2 protein, human)
0 (Sodium-Glucose Transporter 2)
0 (Sodium-Glucose Transporter 2 Inhibitors)
1ULL0QJ8UC (dapagliflozin)

Date Created: 20170704 Date Completed: 20180827 Latest Revision: 20221109

20231215

10.1016/j.pcd.2017.06.004

28669625